Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Michael Baker discusses the company’s collaboration with Imugene to combine therapies.
Arovella Therapeutics intends to be a world leader as a biotechnology company helping people live longer and healthier lives. The company will develop its existing products and look to acquire additional platforms they believe have an impact on the treatment of cancer and conditions that affect the central nervous system.